AbCellera Biologics (NASDAQ:ABCL – Get Free Report) released its earnings results on Monday. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.08, FiscalAI reports. AbCellera Biologics had a negative net margin of 198.37% and a negative return on equity of 15.05%. The firm had revenue of $8.32 million for the quarter, compared to the consensus estimate of $5.86 million. During the same period in the prior year, the firm earned ($0.15) EPS.
Here are the key takeaways from AbCellera Biologics’ conference call:
- Interim Phase I data for ABCL635 showed generally well‑tolerated safety with no liver‑related adverse events, linear PK supporting monthly dosing, and sustained dose‑dependent suppression of testosterone, FSH and LH consistent with strong NK3R target engagement.
- The randomized Phase II (≈80 patients, single 600 mg SC dose) is enrolling and remains on track for a top‑line efficacy/safety readout in Q3 2026; management says a positive result would be highly de‑risking and support late‑stage development and expansion into cancer‑related VMS indications.
- Pipeline progress includes an expected Phase I top‑line for ABCL575 in Q4 2026, two IND‑enabling programs (ABCL688, ABCL386) targeted to reach the clinic by end‑2027, and a planned fifth development candidate selection in H1 2026, though program details remain limited.
- AbCellera ended Q1 with ~CAD 531M cash and marketable securities plus ~CAD 125M committed government funding (≈CAD 655M available liquidity), which management says funds at least three years of pipeline investment despite a Q1 net loss of ~CAD 43M and lower research‑fee revenue as the company shifts to internal programs.
AbCellera Biologics Stock Down 10.9%
Shares of AbCellera Biologics stock opened at $4.68 on Tuesday. AbCellera Biologics has a twelve month low of $1.94 and a twelve month high of $6.51. The company’s 50 day moving average is $3.78 and its 200 day moving average is $3.83. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -9.63 and a beta of 1.02.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Analysis on ABCL
Institutional Investors Weigh In On AbCellera Biologics
A number of hedge funds have recently added to or reduced their stakes in ABCL. Engineers Gate Manager LP purchased a new stake in AbCellera Biologics during the fourth quarter valued at $38,000. Magnetar Financial LLC purchased a new position in AbCellera Biologics in the fourth quarter worth about $49,000. Lantern Wealth Advisors LLC bought a new stake in shares of AbCellera Biologics during the 2nd quarter valued at about $51,000. Oxford Asset Management LLP purchased a new stake in shares of AbCellera Biologics during the 4th quarter valued at about $51,000. Finally, Invesco Ltd. grew its position in AbCellera Biologics by 114.6% during the first quarter. Invesco Ltd. now owns 24,146 shares of the company’s stock valued at $54,000 after buying an additional 12,893 shares during the period. 61.42% of the stock is currently owned by hedge funds and other institutional investors.
AbCellera Biologics Company Profile
AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.
AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.
Read More
- Five stocks we like better than AbCellera Biologics
- AI Demand Fuels Strong Q1 Earnings for Constellation Energy
- Sony’s $4 Billion Bet on Rock & Roll Royalties
- Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It
- TMC Forges a New EV Supply Chain at the Bottom of the Sea
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
